Drugmaker Valeant CEO leaving as investor Ackman joins board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Valeant (VRX) is Not Investable - Piper Jaffray
March 21, 2016 11:34 AM EDTPiper Jaffray analyst David Amsellem weighed in on Valeant Pharmaceuticals (NYSE: VRX) after the company announced this morning that CEO Michael Pearson will be stepping down, and that William Ackman will be joining the Board of Directors. More importantly, the company cited the... More
Valeant Pharma (VRX) Gives Up Gains; Trades Flat
March 21, 2016 9:43 AM EDTValeant Pharma (NYSE: VRX) gives back early gains, now flat
... More